Chemotherapy-induced nausea and vomiting: Current and new standards in the antiemetic prophylaxis and treatment

European Journal of Cancer

Volumn 41, Issue 2, 2005, Pages 199-205

  Jordan, Karin ^a   Kasper, Christoph ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

5 HT 3 receptor antagonists; Anti emetic therapy; Chemotherapy; MASCC guidelines; NCCN guidelines; Neurokinin 1 receptor antagonists; Steroids

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE; CANNABINOID DERIVATIVE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DRONABINOL; DROPERIDOL; GRANISETRON; HALOPERIDOL; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; METOPIMAZINE; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE; SEROTONIN 3 ANTAGONIST; TROPISETRON; UNINDEXED DRUG;

CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; HYPERGLYCEMIA; INSOMNIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 12344249651     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.09.026     Document Type: Article

References (29)

1. Website: http://www.mascc.org Multinational association for supportive care in cancer. Consensus Conference on antiemtic therapy Perugia, March 29-31, 2004
2. D.S. Ettinger, D.D. Kloth, and M.G. Kris National comprehensive cancer network antiemesis Clinical Prac Guidelines Oncol-v 1 2004
3. G.R. Morrow The effect of susceptibility to motion sickness on the side effect of cancer chemotherapy Cancer 55 1985 2766 2770
4. D. Osoba, B. Zee, and J. Pater Determinants of postchemotherapy nausea and vomiting in patients with cancer J Clin Oncol 15 1997 116 123
5. P.J. Hesketh, S.M. Grunberg, and R.J. Graua The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin J Clin Oncol 21 2003 4112 4119
6. S. Poli-Bigelli, J. Rodrigues-Pereira, and A.D. Carides Addition of the neurokinin1 receptor antagonist aprepitant to standard anti-emetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 2003 3090 3098
7. J. Herrstedt Risk-benefit of antiemetics in prevention and treatment of chemotherapy nausea and vomiting Exp Opin Drug Safe 3 2004 231 248
8. K. Jordan, A. Hinke, and A. Grothey A meta-analysis comparing the efficacy of five 5-HT-3 receptor-antagonists (5-HT3-Ras) for acute chemotherapy induced emesis Proc Am Soc Clin Oncol 23 2004 #8048
9. R.J. Gralla, D. Osoba, and M.G. Kris Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines J Clin Oncol 17 1999 2971 2994
10. J.M. Koeller, M.S. Aapro, and R.J. Gralla Antiemetic guidelines: creating a more practical treatment approach Support Care Cancer 10 2002 519 522
11. I. Herr, E. Ucur, and K. Herzer Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas Cancer Res 63 2003 3112 3120
12. N. Kemeny, M. Gonen, and D. Sullivan Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer J Clin Oncol 10 2001 2687 2695
13. The Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998, 16, 2937-2942
14. The Italian Group for Antiemetic Research. Randomized, Double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004, 22, 725-729
15. S.P. Chawla, S.M. Grunberg, and R.J. Gralla Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting Cancer 97 2003 2290 2300
16. Website: www.fda.gov, Merck background package for the FDA
17. J. Herrstedt, M.S. Aapro, and J.F. Smyth Corticosteroids, dopamine antagonists and other drugs Support Care Cancer 6 1998 204 214
18. P.J. Ison, and S.J. Peroutka Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects Cancer Treat Rep 70 1986 637 641
19. M.G. Kris, R.J. Gralla, and R.A. Clark Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial Cancer 11 1987 2816 2822
20. K.A. Mannix Palliation of nausea and vomiting D. Doyle G. Hanks N. Cherny K. Calmann Oxford textbook of palliative medicine 2004 Oxford University Press Oxford, UK 459 467
21. R.J. Gralla, L.B. Tyson, and L.A. Bordin Antiemetic therapy: a review of recent studies and a report of a random assignement trial comparing metoclopramide with delta-9-tetrahydrocannabinol Cancer Treat Rep 68 1984 163 172
22. D.G. Warr, P. Eisenberg, and P.J. Hesketh Phase III, double- blind study to assess an aprepitant-containing regimen for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy Proc Am Soc Clin Oncol 23 2004 #8007
23. R. De Wit Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics Br J Can 88 2003 1823 1827
24. G.R. Morrow, and J.A. Roscoe Anticipatory nausea and vomiting: models, mechanisms and management M.A. Dicato Medical management of cancer treatment induced emesis 1998 Dunitz London 149 166
25. M.S. Aapro How do we manage patients with refractory or breaktrough emesis? Support Care Cancer 10 2002 106 109
26. J. Carmichael, H.J. Keizer, and D. Cupissol Use of granisetron in patients refractory to previous treatment with antiemetics Anticancer Drugs 5 1998 381 385
27. R. Kaiser, O. Sezer, and A. Papies Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes J Clin Oncol 20 2002 2805 2811
28. F. Roila, D. Donati, and S. Tamberi Delayed emesis: incidence, pattern, prognostic factors and optimal treatment Support Care Cancer 10 2002 88 95
29. P.J. Hesketh, M.G. Kris, and S.M. Grunberg Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 1997 103 109